Klin Farmakol Farm. 2010;24(1):51-56

Pharmacokinetics and clinical applications of selected immunosuppressants II

Petra Halvová, Milan Grundmann
Ústav klinické farmakologie, FN a FZS Ostrava
Ostravská univerzita, Ostrava

The currently available immunosuppressive agents have been used for the management of patient with a wide range of medicinal issues,

such as organ transplantation, autoimmune diseases, asthma, and rheumatoid arthritis, among others. All of the agents have relatively

narrow therapeutic ranges with significant dose-limiting toxicities. This review discusses pharmacodynamic properties, biotransformation,

drug interactions, and side effects of calcineurin inhibitors, mTOR inhibitors, mycophenolat, cyclophosphamide, and methotrexate.

Keywords: immunosuppressive agents, calcineurin inhibitors, mTOR inhibitors, mycophenolat

Published: May 1, 2010  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Halvová P, Grundmann M. Pharmacokinetics and clinical applications of selected immunosuppressants II. Klin Farmakol Farm. 2010;24(1):51-56.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Maršálková P, Grundmann M. Farmakokinetika a kinické aplikace vybraných imunosupresiv I. Klin Farmakol Farm 2009; 23(3): 138-141.
    2. Trevillian P. The CARI guidelines. Calcineurin inhibitors in renal transplantation: therapeutic drug monitoring. Nephrology (Carlton) 2007; 12(Suppl 1): S57-65. Go to original source... Go to PubMed...
    3. Taylor AL, Watson CJ, Bradley JA. Immunosuppressive agents in solid organ transplantation: Mechanisms of action and therapeutic efficacy. Crit Rev Oncol Hematol 2005; 56(1): 23-46. Go to original source... Go to PubMed...
    4. Masri MA. The mosaic of immunosuppressive drugs. Mol Immunol 2003; 39(17-18): 1073-1077. Go to original source... Go to PubMed...
    5. Dirks NL, Huth B, Yates CR, Meibohm B. Pharmacokinetics of immunosuppressants: a perspective on ethnic differences. Int J Clin Pharmacol Ther 2004; 42(12): 701-718. Go to original source... Go to PubMed...
    6. Kahan BD, Shaw LM, Holt D, Grevel J, Johnston A. Consensus document: Hawk's Cay meeting on therapeutic drug monitoring of cyclosporine. Clin Chem 1990; 36(8 Pt 1): 1510-1516. Go to original source...
    7. Elbarbry FA, Marfleet T, Shoker AS. Drug-drug interactions with immunosuppressive agents: review of the in vitro functional assays and role of cytochrome P450 enzymes. Transplantation 2008; 85(9): 1222-1229. Go to original source... Go to PubMed...
    8. Keogh A, Day R, Critchley L, Duggin G, Baron D. The effect of food and cholestyramine on the absorption of cyclosporine in cardiac transplant recipients. Transplant Proc 1988; 20(1): 27-30.
    9. Yatscoff RW, Aspeslet LJ. The monitoring of immunosuppressive drugs: a pharmacodynamic approach. Ther Drug Monit 1998; 20(5): 459-463. Go to original source... Go to PubMed...
    10. Shaw LM, Figurski M, Milone MC, Trofe J, Bloom RD. Therapeutic drug monitoring of mycophenolic acid. Clin J Am Soc Nephrol 2007; 2(5): 1062-1072. Go to original source... Go to PubMed...
    11. Terada N, Lucas JJ, Szepesi A, Franklin RA, Domenico J, Gelfand EW. Rapamycin blocks cell cycle progression of activated T cells prior to events characteristic of the middle to late G1 phase of the cycle. J Cell Physiol 1993; 154(1): 7-15. Go to original source... Go to PubMed...
    12. Genestier L, Paillot R, Fournel S, Ferraro C, Miossec P, Revillard JP. Immunosuppressive properties of methotrexate: apoptosis and clonal deletion of activated peripheral T cells. J Clin Invest 1998; 102(2): 322-328. Go to original source... Go to PubMed...
    13. Swierkot J, Szechinski J. Methotrexate in rheumatoid arthritis. Pharmacol Rep 2006; 58(4): 473-492. Go to PubMed...
    14. Harný J, Grundmann M. Léčba ALL u dětí s vysokodávkovaným metotrexátem. Čs. pediatrie 1994; 3: 172-175.
    15. Harný J, Grundmann M, Brosmanová H, Blažek B, Šterba J. High-dose methotrexate for the treatment of acute lympho - blastic leukemia in children (a pharmacokinetic study). Drug Rezistance in Leukemia and Lymphoma II, Harwood A cad. Publishers 1997; 183-188.

    Return to the content


    Clinical Pharmacology and Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.